Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cost Utility Analyses of Adalimumab Treatment in Patients With Rheumatoid Arthritis.

Next Previous
Trial Profile

Cost Utility Analyses of Adalimumab Treatment in Patients With Rheumatoid Arthritis.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 17 Aug 2011

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms HEOR
  • Sponsors Abbott Laboratories

Most Recent Events

  • 20 Oct 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
  • 20 Oct 2010 Actual end date (June 2010) added as reported by ClinicalTrials.gov.
  • 12 Jul 2010 Planned end date changed from 1 Jun 2010 to 1 Nov 2010 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top